clinicaltrialsarena11h
Arch Biopartners doses first subject in trial of acute kidney injury treatment
Arch Biopartners has dosed the first patient in Canada in its Phase II clinical trial of LSALT peptide (Metablok) for acute ...
clinicaltrialsarena14h
AbbVie’s stock plummets over 12% after schizophrenia drug flops in Phase II trials
AbbVie’s stock price fell over 12% after emraclidine failed to meet its primary endpoints in the company’s Phase II ...
clinicaltrialsarena15h
Neurogene’s stock sinks after adverse event with Rett syndrome gene therapy
Neurogene's stock price collapsed by 34.8% in pre-market trading after announcing data from the Phase I/II Rett syndrome ...
clinicaltrialsarena15h
Cerevance reports results from trial of CVN293 for neurodegenerative conditions
Cerevance has announced positive outcomes from its Phase I trial of CVN293, a drug candidate designed to treat ...
clinicaltrialsarena16h
ViiV Healthcare shares results from trial of Dovato and three-drug therapy for HIV
ViiV Healthcare has reported results from a trial of Dovato, a two-drug regimen consisting of dolutegravir/lamivudine ...